MedTrace Logo

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05891197 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-07-01

No results posted yet for this study

Summary

Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.

Conditions

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • Lyell Immunopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jackie Walling, MBChB, PhD · Lyell Immunopharma

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-19
Primary Completion
2025-02-05
Completion
2025-02-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891197 on ClinicalTrials.gov